

SHORT REPORT

***PTPN22* R620W minor allele is a genetic risk factor for giant cell arteritis**

Susan Lester,^{1,2} Alex W Hewitt,³ Carlee D Ruediger,^{1,2} Linda Bradbury,^{4,5} Elisabeth De Smit,⁶ Michael D Wiese,⁷ Rachel Black,¹ Andrew Harrison,⁸ Graeme Jones,⁹ Geoffrey O Littlejohn,¹⁰ Tony R Merriman,¹¹ Bain Shenhstone,¹² Malcolm D Smith,¹³ Maureen Rischmueller,^{1,2} Matthew A Brown,^{4,5} Catherine L Hill^{1,2,14}

To cite: Lester S, Hewitt AW, Ruediger CD, *et al.* *PTPN22* R620W minor allele is a genetic risk factor for giant cell arteritis. *RMD Open* 2016;**2**:e000246. doi:10.1136/rmdopen-2016-000246

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/rmdopen-2016-000246>).

Received 10 January 2016
Revised 3 March 2016
Accepted 8 March 2016



CrossMark

For numbered affiliations see end of article.

Correspondence to

Susan Lester;
susan.lester@sa.gov.au

ABSTRACT

Giant cell arteritis (GCA) is one of the commonest forms of vasculitis in the elderly, and may result in blindness and stroke. The pathogenesis of GCA is not understood, although environmental, infectious and genetic risk factors are implicated. One gene of interest is *PTPN22*, encoding lymphoid protein tyrosine phosphatase (Lyp), expressed exclusively in immune cells, which is proposed to be an 'archetypal non-HLA autoimmunity gene'. The minor allele of a functional *PTPN22* single nucleotide polymorphism (rs2476601, R620W), which disrupts an interaction motif in the protein, was originally reported to be associated with biopsy-proven GCA in Spanish patients, with supporting data from three replicate Northern European studies. Recently, this observation was extended with additional patients and controls, and studies encompassing European, Scandinavian, UK and American patients. The aim of our study was to determine the association between *PTPN22* rs2476601 (R620W) and biopsy-proven GCA in an Australian case cohort.

Giant cell arteritis (GCA) is one of the commonest forms of vasculitis in the elderly, and may result in blindness and stroke.¹ The pathogenesis of GCA is not understood, although environmental, infectious and genetic risk factors are implicated. One gene of interest is *PTPN22*, encoding lymphoid protein tyrosine phosphatase (Lyp), expressed exclusively in immune cells, which is proposed to be an 'archetypal non-HLA autoimmunity gene'.^{2,3} The minor allele of a functional *PTPN22* single nucleotide polymorphism (rs2476601, R620W), which disrupts an interaction motif in the protein, was originally reported to be associated with biopsy-proven GCA in Spanish patients, with supporting data from three replicate Northern European studies.⁴ Recently, this observation was extended with additional

Key messages

- *PTPN22* may be an archetypal autoimmunity gene.
- In this study we have estimated the frequency of the *PTPN22* rs2476601 (R620W) variant in Australian Giant Cell Arteritis (GCA) patients of European ancestry compared to population based controls.
- Meta-analysis of all available studies from populations of both Northern and Southern European ancestry, confirm an association between the rs2476601 minor allele variant and GCA.

patients and controls, and studies encompassing European, Scandinavian, UK and American patients.⁵ The aim of our study was to determine the association between *PTPN22* rs2476601 (R620W) and biopsy-proven GCA in an Australian case cohort.

Australian patients with biopsy-proven GCA were recruited through the Arthritis Genomics Recruitment Initiative in Australasia (AGRIA), and the study consisted of 209 patients with biopsy-proven GCA and 455 South Australian European-ancestry population-based controls. The mean age of the patients with biopsy-proven GCA was 73 years, 66% were female, 70% presented with temporal headache, 1% with scalp tenderness, 54% with jaw claudication, 31% with visual disturbance, 4% with stroke and 40% with concurrent polymyalgia rheumatica.

rs2476601 Genotyping was performed using a Taqman allelic discrimination assay (C-16021387) on a Viia7 Real-Time PCR System (Applied Biosystems, Foster City, California, USA). A random-effects meta-analysis, based on the allele frequencies from all cohorts,⁵ was performed using the R library metafor.⁶

Table 1 Genotype distribution and minor (A) allele frequency of *PTPN22* rs2476601 in Australian patients with giant cell arteritis (GCA) and controls

Group	n	Genotype			Minor allele (A) Frequency	Minor allele OR (95% CI)	p Value
		GG	AG	AA			
Control	455	381	73	1	0.082	1	0.51
GCA	209	174	31	4	0.093	1.15 (0.76 to 1.72)	

rs2476601 Genotypes and allele frequencies for Australian patients with GCA and controls are reported in table 1. The genotypes of the control population were in Hardy-Weinberg equilibrium ($p=0.19$). Although not reaching statistical significance, there was a trend towards an excess of minor (A) allele homozygosity within patients with GCA ($p=0.09$). There was a small increase in the minor (A) allele frequency in patients with GCA (OR 1.15, 95% CI 0.76 to 1.72), but this did not reach statistical significance ($p=0.51$).

The meta-analysis of rs2476601 minor allele frequencies from all available GCA case-control studies is reported in figure 1. The effect size from our Australian study is in keeping with the findings from other studies of patients with Northern European ancestry. While the majority of these GCA studies, including ours, were underpowered to detect an association, the results from each study are remarkably consistent and collectively indicate a significant association between the rs2476601 minor allele and GCA (OR 1.33, 95% CI 1.16 to 1.52, $p=3 \times 10^{-5}$).

Although not quite reaching statistical significance, there was also a trend towards larger effect sizes for studies involving Southern European ancestry participants ($p=0.054$). In this context, it is interesting that the risk of GCA, which is highest in Northern European

populations (about 20 cases per 100 000 persons older than 50 years) and lower in Southern European populations (about 10 cases per 100 000),⁷ parallels a similar North-South cline in rs2476601 minor allele frequencies across Europe.³ Therefore, it is possible that *PTPN22* rs2476601 minor allele contributes more to GCA risk on a non-Northern European genetic background, or alternatively, that GCA cases from Southern Europe have more Northern European ancestry than population-matched controls.

A limitation of this study is that the most appropriate genetic association model was not determined because full genotype information was only available for the Australian data. Interestingly, using the Australian data, the Akaike information criterion (AIC) suggested that the recessive association model (AIC 826.1) was slightly better than either the additive (AIC 830.7) or dominant models (AIC 831.1). However, given that only five minor allele homozygotes were observed in a total of 664 participants, there was insufficient information to determine the most appropriate model.

In summary, there is a significant association between the minor allele of *PTPN22* rs2476601 and GCA, although the pathogenic mechanism remains to be elucidated. Power is a limiting factor in GCA genetic association studies due to difficulties in recruitment of elderly patients. However, this example illustrates the value of data from multiple, yet small, studies in delivering robust findings.

Author affiliations

¹Department of Rheumatology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia

²Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia

³Genetics and Population Health, University of Western Australia, Perth, Western Australia, Australia

⁴Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Qld, Australia

⁵University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Qld, Australia

⁶Centre for Eye Research, Melbourne, Victoria, Australia

⁷School of Pharmacy and Medical Sciences, University of South Australia, Australia

⁸Department of Medicine, University of Otago Wellington, Wellington, New Zealand

⁹Department of Rheumatology, Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia

¹⁰Department of Rheumatology, Monash Medical Centre, Clayton, Victoria, Australia




Figure 1 Random-effects (RE) meta-analysis of *PTPN22* rs2476601 minor (A) allele frequencies in patients with giant cell arteritis (GCA) (n=1860) compared to controls (n=15 761). Data from the current Australian study was combined with previously reported case-control studies.⁵ Results between the studies were consistent: τ^2 was estimated as 0.0034 (on the log scale), and there was no substantive heterogeneity ($Q=4.72$, $df=6$, $p=0.58$). The difference in effect sizes between Northern and Southern European ancestry studies did not reach statistical significance ($p=0.054$).

¹¹Department of Biochemistry, University of Otago, Dunedin, New Zealand

¹²Department of Rheumatology Concord Hospital, Concord, New South Wales, Australia

¹³Department of Medicine, Flinders Medical Centre and Repatriation General Hospital, Adelaide, South Australia, Australia

¹⁴The Health Observatory, University of Adelaide, Adelaide, South Australia, Australia

Acknowledgements The authors wish to thank the Chief Investigators, study team, and participants of the North West Adelaide Health (NWAH) Study for the contribution of control samples for this study.

Contributors SL assisted with the conception and design of the work, genotyping, analysis and interpretation of the data, drafting the work and revising it critically for important intellectual content and gave final approval for the version published. AWH, LB, EDS, MDW, AH, GOL, TRM, BS, MDS, MR and MAB drafted the work and revised the manuscript. CDR conducted patient and control recruitment, analysed the data, drafted the work and revised the manuscript. GJ gave final approval for the version published. CLH assisted with patient and control recruitment, gave final approval for the version published, and substantial contributions to the conception and design of the work, drafting the work, revising the manuscript and final approval for the version published.

Funding National Health and Medical Research Council, Arthritis Australia (grant number 1068023).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Human Research Ethics Committee (TQEH/LMH/MH).

Provenance and peer review Not commissioned, externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. González-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. *Curr Rheumatol Rep* 2015;17:6.
2. Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmunity gene. *Nat Rev Rheumatol* 2014;10:602–11.
3. Gregersen PK, Lee HS, Battilwalla F, *et al.* PTPN22: setting thresholds for autoimmunity. *Semin Immunol* 2006;18:214–23.
4. Serrano A, Márquez A, Mackie SL, *et al.*, UK GCA Consortium Spanish GCA Consortium. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. *Ann Rheum Dis* 2013;72:1882–6.
5. Carmona FD, Mackie SL, Martin JE, *et al.* A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. *Am J Hum Genet* 2015;96:565–80.
6. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Software* 2010;36:1–48.
7. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. *N Engl J Med* 2014;371:1653.